Skip to main content
PAINWeek 2025 Main banner
Icon Legend
This session is not in your agenda.
This session is in your agenda. Click to remove it

Seth Lederman, MD

CEO
Tonix Pharmaceuticals, Inc.
Chatham, New Jersey

Seth Lederman is a physician, scientist, drug-hunter, biopharmaceutical executive, and a co-founder and chief executive officer of Tonix Pharmaceuticals (TNXP, Nasdaq). Tonix is developing TNX-102 SL (cyclobenzaprine HCl sublingual tablets) as a treatment for fibromyalgia. The U.S. Food and Drug Administration (FDA) has set August 15, 2025 as a goal date for a decision on marketing authorization for TNX-102 SL. If approved, TNX-102 SL would be the first new drug for fibromyalgia in over 15 years and the first member of a new class of drugs for fibromyalgia. TNX-102 SL is an investigational new drug and is not approved for any indication. Prior to becoming a biopharma executive, Dr. Lederman served as an Associate Professor at Columbia University and directed basic science research in molecular immunology, infectious disease and the development of therapeutics for autoimmune diseases. His fundamental work on the CD40-Ligand (CD154) elucidated the molecular basis of T cell helper function and has led to the development of therapeutic candidates for autoimmune diseases and organ transplant rejection. In addition to his research, Dr. Lederman served as attending physician in the Edward Daniels Arthritis and Autoimmunity Clinic on the Medical Service at Columbia Presbyterian Hospital for several years. Dr. Lederman earned his MD from Columbia University’s College of Physicians and Surgeons and an AB from Princeton in Chemistry cum laude.

Presentation(s):